Johnson & Johnson discontinues the Phase 3 SunRISe-2 trial for TAR-200 in bladder cancer, citing lack of superiority. Q3 ...

TORONTO, ON / ACCESSWIRE / October 7, 2024 / Theralase® Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development ...

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.

Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug ...

The SWOG S1011 trial shows no survival benefit from extended lymphadenectomy in bladder cancer, revealing higher complications and mortality post-surgery.

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher ...

Final results from the SWOG S1011 randomized Phase III clinical trial, published in the New England Journal of Medicine, ...

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher ...